Skip to main content
. 2021 Jul 22;12:690860. doi: 10.3389/fgene.2021.690860

Table 4.

Summary of OR and 95% CIs of NLRP3 rs10754558 polymorphism and AIDs susceptibility for various comparisons.

Stratification N GG vs. CC GC vs. CC GG/GC vs. CC GG vs. GC/CC G vs. C
OR (95% CIs) Ph OR (95% CIs) Ph OR (95% CIs) Ph OR (95% CIs) Ph OR (95% CIs) Ph
Total 8 0.63 (0.51, 0.77) 0.345 0.78 (0.66, 0.91) 0.082 0.73 (0.63, 0.84) 0.096 0.73 (0.62, 0.88) 0.370 0.78 (0.71, 0.87) 0.159
Ethnicity
European 1 0.90 (0.59, 1.39) NA 1.06 (0.75, 1.50) NA 1.01 (0.73, 1.41) NA 0.87 (0.60, 1.26) NA 0.96 (0.78, 1.19) NA
Latin American 4 0.45 (0.33, 0.62) 0.941 0.64 (0.51, 0.81) 0.854 0.58 (0.47, 0.72) 0.945 0.58 (0.44, 0.78) 0.817 0.65 (0.56, 0.76) 0.935
Arab 2 0.71 (0.38, 1.32) 0.844 0.50 (0.30, 0.82) 0.550 0.55 (0.34, 0.89) 0.713 1.15 (0.70, 1.91) 0.531 0.84 (0.63, 1.12) 0.905
Asian 1 0.73 (0.50, 1.08) NA 1.01 (0.74, 1.39) NA 0.92 (0.68, 1.23) NA 0.72 (0.51, 1.02) NA 0.86 (0.71, 1.05) NA
Disease type
T1D 1 0.45 (0.25, 0.81) NA 0.69 (0.44, 1.07) NA 0.61 (0.41, 0.91) NA 0.55 (0.32, 0.93) NA 0.64 (0.48, 0.86) NA
CD 2 0.76 (0.52, 1.12) 0.090 0.99 (0.73, 1.34) 0.373 0.91(0.68, 1.21) 0.175 0.77 (0.55, 1.08) 0.141 0.88 (0.73, 1.07) 0.08
MS 1 0.74 (0.34, 1.61) NA 0.44 (0.24, 0.84) NA 0.51 (0.28, 0.94) NA 1.30 (0.69, 2.43) NA 0.85 (0.60, 1.22) NA
RA 1 0.45 (0.27, 0.76) NA 0.57 (0.39, 0.84) NA 0.53 (0.37, 0.76) NA 0.61 (0.37, 0.98) NA 0.63 (0.49, 0.81) NA
SLE 2 0.67 (0.48, 0.94) 0.403 0.89 (0.68, 1.17) 0.129 0.82 (0.64, 1.05) 0.151 0.72 (0.53, 0.96) 0.898 0.82 (0.69, 0.97) 0.331
MG 1 0.65 (0.23, 1.84) NA 0.78 (0.66, 0.91) NA 0.62 (0.28, 1.38) NA 0.93 (0.40, 2.16) NA 0.82 (0.51, 1.32) NA

N, number of studies involved; Ph, p-value of Q-test for heterogeneity test; OR, odds ratios; NA, not available; T1D, type 1 diabetes; CD, celiac disease; MS, multiple sclerosis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; MG, myasthenia gravis.